STOCK TITAN

Verona Pharma to Present at Jefferies Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Verona Pharma (Nasdaq: VRNA) will have its Senior Vice President of Commercial, Chris Martin, present at the Jefferies Healthcare Conference on June 8, 2022, at 1:30 PM ET. This event will be accessible via a webcast on the company's website. Verona Pharma is a clinical-stage biopharmaceutical company focused on respiratory diseases, currently evaluating nebulized ensifentrine in a Phase 3 clinical program for COPD. Top-line data for this study is anticipated in the third quarter of 2022, with ensifentrine aiming to be a dual-action therapy.

Positive
  • None.
Negative
  • None.

LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces that Chris Martin, Senior Vice President of Commercial, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:30 PM ET / 6:30 PM BST.

A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on respiratory diseases. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Top-line data are expected in the third quarter of 2022 and around the end of 2022.

If successfully developed and approved, ensifentrine has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

For further information please contact:

Verona Pharma plcUS Tel: +1-833-417-0262
UK Tel: +44 (0)203 283 4200
Victoria Stewart, Director of Investor Relations and Communicationsinfo@veronapharma.com
  
Argot Partners
(US Investor Enquiries)
Tel: +1-212-600-1902
verona@argotpartners.com
Kimberly Minarovich / Michael Barron 
  
Optimum Strategic Communications
(International Media and European Investor Enquiries)
Tel: +44 (0)203 950 9144
verona@optimumcomms.com
Mary Clark / Rebecca Noonan / Zoe Bolt 

 


FAQ

When will Verona Pharma present at the Jefferies Healthcare Conference?

Verona Pharma will present on June 8, 2022, at 1:30 PM ET.

What is the focus of Verona Pharma's clinical programs?

Verona Pharma focuses on respiratory diseases, particularly COPD, with its nebulized ensifentrine.

What data is Verona Pharma expecting in 2022?

Top-line data from the Phase 3 clinical program for ensifentrine is expected in the third quarter of 2022.

How does ensifentrine work for COPD treatment?

Ensifentrine combines bronchodilator and anti-inflammatory properties in one compound.

Where can I access the webcast of Verona Pharma's presentation?

The webcast will be available on the Investors page of Verona Pharma's website.

Verona Pharma plc

NASDAQ:VRNA

VRNA Rankings

VRNA Latest News

VRNA Stock Data

3.18B
68.54M
4.11%
89.37%
9.19%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LONDON